CN116983267A - Embedding system of dihydrocannabidiol dinitrate and preparation method and application thereof - Google Patents

Embedding system of dihydrocannabidiol dinitrate and preparation method and application thereof Download PDF

Info

Publication number
CN116983267A
CN116983267A CN202311266164.4A CN202311266164A CN116983267A CN 116983267 A CN116983267 A CN 116983267A CN 202311266164 A CN202311266164 A CN 202311266164A CN 116983267 A CN116983267 A CN 116983267A
Authority
CN
China
Prior art keywords
dihydrocannabidiol
dinitrate
preparation
shearing
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202311266164.4A
Other languages
Chinese (zh)
Other versions
CN116983267B (en
Inventor
王凤忠
范蓓
王博
孙玉凤
佟立涛
唐璐
鲁为
孙源
张亮
孙晶
卢聪
刘佳萌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heilongjiang Fengyou Hemp Planting Co ltd
Original Assignee
Institute of Food Science and Technology of CAAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Food Science and Technology of CAAS filed Critical Institute of Food Science and Technology of CAAS
Priority to CN202311266164.4A priority Critical patent/CN116983267B/en
Publication of CN116983267A publication Critical patent/CN116983267A/en
Application granted granted Critical
Publication of CN116983267B publication Critical patent/CN116983267B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The invention discloses an embedding system of dihydrocannabidiol dinitrate and a preparation method and application thereof, wherein the preparation method comprises the following steps: mixing cannabidiol, an organic solvent A and a catalytic system to obtain dihydro cannabidiol; mixing the dihydrocannabidiol, the organic solvent B and the 6-chloronicotinyl chloride to obtain dihydrocannabidiol dinicotinate; and dissolving the dihydrocannabidiol dinitrate in an organic solvent C to obtain an oil solution, mixing the oil solution with a cellulose nanocrystalline suspension, and shearing to obtain an embedding system of the dihydrocannabidiol dinitrate. The dihydrocannabidiol dinitrate and the embedding system thereof have good stability, have a protective effect on nerve cell injury and a relieving effect on insulin resistance, can be used for preparing nerve cell protective medicaments and hypoglycemic medicaments, and have practical application values in medical production.

Description

Embedding system of dihydrocannabidiol dinitrate and preparation method and application thereof
Technical Field
The invention belongs to the technical field of chemical industry, and particularly relates to an embedding system of dihydrocannabidiol dinitrate, and a preparation method and application thereof.
Background
Industrial cannabis is a Sang Keda cannabis plant, has important medicinal value, and the terpenoid secondary metabolite, namely cannabinoid, has various biological activities. Tetrahydrocannabinol (THC) and Cannabidiol (CBD) are the higher content components of cannabinoids. While tetrahydrocannabinol is useful in the treatment of emesis caused by cancer, it is prohibited in many countries because of its addictive nature. Unlike tetrahydrocannabinol, cannabidiol has no mental addiction, and has anticonvulsant, sedative-hypnotic, anxiolytic, antipsychotic, antiinflammatory and neuroprotective effects, and is a natural active ingredient with great application prospect in the fields of medicine, cosmetics and food.
The current studies indicate that cannabidiol can produce tetrahydrocannabinol in artificial gastric juice containing ethanol (Zhang Xuran, fan Dekai, sun Wuxing, etc. CBD and water-soluble CBD are stable in artificial gastric juice, intestinal juice for research on green technology, 2020, 8:5). Additional studies have shown that cannabidiol can be converted to tetrahydrocannabinol under acidic conditions (Michal P. Dybowski, andrzej L. Dawidowicz, rafal Typek, michal Rombel Conversion of Cannabidiol (CBD) to Δ9-tetrahydrocanabinol (Δ9-THC) during protein precipitations prior to plasma samples analysis by chromatography-Troubles with reliable CBD quantitation when acidic precipitation agents are applied Talanta, 2020, 220: 121390). Therefore, the possibility of formation of tetrahydrocannabinol is eliminated, the key for guaranteeing the use safety of tetrahydrocannabinol is provided, and the application scene of tetrahydrocannabinol can be greatly expanded. The dihydrocannabidiol is used as a derivative of cannabidiol, is not present in cannabidiol extract, and cannot be converted into tetrahydrocannabidiol in vivo or by other synthetic means, and has better safety than cannabidiol.
Therefore, the designed and synthesized dihydrocannabidiol derivative based on the cannabidiol structure can be used as an important way for obtaining the compound with good stability and activity, and has important significance for preparing novel medicines.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides an embedding system of dihydrocannabidiol dinitrate, and a preparation method and application thereof. The research shows that the dihydrocannabidiol dinitrate and the embedding system thereof have better nerve cell protection effect and blood sugar reducing effect.
In a first aspect of the present invention, there is provided a method for preparing an embedding system of dihydrocannabidiol dinitrate, said method comprising the steps of:
(1) Preparation of dihydrocannabidiol dinitrate:
a: mixing cannabidiol, an organic solvent A and a catalytic system to obtain dihydro cannabidiol;
b: mixing the dihydrocannabidiol, the organic solvent B and the 6-chloronicotinyl chloride to obtain dihydrocannabidiol dinicotinate;
(2) Preparing an embedding system:
and dissolving the dihydrocannabidiol dinitrate in an organic solvent C to obtain an oil solution, mixing the oil solution with a cellulose nanocrystalline suspension, and shearing to obtain an embedding system of the dihydrocannabidiol dinitrate.
Further, the structure of the dihydrocannabidiol dinitrate is shown as a formula I:
。
further, the organic solvent A is selected from one or more of dichloromethane, cyclohexane, methanol, ethanol, isopropanol, diethyl ether, chloroform, propylene glycol, n-butanol, acetone, tetrahydrofuran and xylene, in particular dichloromethane.
Further, the catalytic system is a catalyst and/or hydrogen.
Further, the catalyst is a metal catalyst and/or a carbon carrier.
Further, the pressure of the hydrogen gas is 1-5 MPa, specifically 1, 2, 3, 4, 5 MPa, especially 2 MPa.
Further, the metal catalyst is selected from one or more of platinum (Pt), palladium (Pd), rhodium (Rh), molybdenum (Mo), tin (Sn) and uranium (Ur), in particular palladium.
Further, the carbon support is selected from one or more of activated carbon (C), carbon nanotubes, activated carbon fibers, graphene, and carbon black, in particular activated carbon.
In some embodiments of the invention, the catalytic system is a 10% palladium on carbon catalyst.
Further, the mass ratio of cannabidiol to the catalytic system is 10-30:1, specifically 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1, 30:1.
In some embodiments of the invention, the mass ratio of cannabidiol to catalytic system is 20:1.
Further, in the step A, the reaction time is 4-12 h, especially 6 h.
Further, the organic solvent B is selected from one or more of dichloromethane, cyclohexane, methanol, ethanol, isopropanol, diethyl ether, chloroform, propylene glycol, n-butanol, acetone, tetrahydrofuran and xylene, in particular dichloromethane.
Further, the molar ratio of the dihydrocannabidiol to the 6-chloronicotinyl chloride is 1:2-4, such as 1:2, 1:3 and 1:4.
In some embodiments of the invention, the molar ratio of dihydrocannabidiol to 6-chloronicotinyl chloride is 1:3.
Further, in step B, the reaction time is 6-24 h, especially 12-h.
Further, in the step B, the reaction is performed at room temperature.
Further, the organic solvent C is selected from one or more of dichloromethane, cyclohexane, methanol, ethanol, isopropanol, diethyl ether, chloroform, propylene glycol, n-butanol, acetone, tetrahydrofuran and xylene, especially propylene glycol.
Further, the oil solution has a mass concentration of 0.1-5%, such as 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5%, especially 2%.
Further, the mass concentration of the cellulose nanocrystal suspension is 0.01-2%, such as 0.01, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2%, especially 0.2%.
Further, the volume ratio of the oil solution to the cellulose nanocrystal suspension is 1:0.1-5, such as 1:0.1, 1:0.5, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, especially 1:1.
Further, the shearing method is selected from one or more of ultrasonic shearing, mechanical shearing, laser shearing, thermal shearing and water jet shearing, and particularly ultrasonic shearing.
Further, the parameters of the ultrasonic shearing are as follows: the ultrasonic power is 100-1000W (such as 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000W), and the ultrasonic time is 1-10 min (such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 min).
In some embodiments of the invention, the parameters of the ultrasonic shearing are: the ultrasonic power is 400W and the ultrasonic time is 5min.
In some embodiments of the present invention, the step (1) specifically includes: mixing cannabidiol, dichloromethane and 10% Pd/C, replacing nitrogen for 3 times, replacing hydrogen for 3 times, reacting for 6 hours under 2Mpa hydrogen, filtering, concentrating by rotary evaporation, and separating and purifying by column chromatography to obtain the dihydrocannabidiol; mixing the dihydrocannabidiol, 6-chloronicotinyl chloride and dichloromethane, reacting for 12 hours at room temperature, concentrating by rotary evaporation, dissolving with dichloromethane, washing by water, drying by anhydrous magnesium sulfate, rotary evaporation, separating and purifying by column chromatography to obtain the dihydrocannabidiol dinitrate.
In some embodiments of the present invention, the step (2) specifically includes: dissolving dihydrocannabidiol dinitrate in propylene glycol to obtain an oil solution of dihydrocannabidiol dinitrate; and (3) carrying out ultrasonic shearing on the oil solution of the dihydrocannabidiol dinitrate and the cellulose nanocrystalline suspension to obtain an embedding system of the dihydrocannabidiol dinitrate.
In a second aspect of the present invention, there is provided an embedding system of dihydrocannabidiol dinitrate prepared by the method of preparation as described in the first aspect.
In a third aspect of the present invention, there is provided a process for the preparation of dihydrocannabidiol dinitrate as described in the first aspect.
In a fourth aspect of the present invention there is provided a dihydrocannabidiol dinitrate prepared by the method of the third aspect.
In a fifth aspect, the invention provides an embedding system of dihydrocannabidiol dinitrate as described in the second aspect for use in the preparation of a hypoglycemic agent.
In a sixth aspect, the present invention provides the use of an embedding system of dihydrocannabidiol dinitrate as described in the second aspect for the preparation of a neuroprotective medicament.
In a seventh aspect, the present invention provides the use of dihydrocannabidiol dinitrate as described in the fourth aspect for the preparation of a hypoglycemic agent.
In an eighth aspect, the present invention provides the use of a dihydrocannabidiol dinitrate as described in the fourth aspect for the preparation of a medicament for protecting nerve cells.
In a ninth aspect of the present invention there is provided a pharmaceutical composition comprising a dihydrocannabidiol dinitrate as described in the fourth aspect, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or an entrapment system of a dihydrocannabidiol dinitrate as described in the second aspect.
Further, the pharmaceutical composition also comprises pharmaceutically acceptable auxiliary materials.
Further, the pharmaceutically acceptable auxiliary materials comprise excipient, diluent, filler and the like.
Further, the dosage form of the pharmaceutical composition is powder or granule.
The invention has the following beneficial effects:
(1) The dihydrocannabidiol dinitrate and the embedding system thereof have good stability, have a protective effect on nerve cell injury and a relieving effect on insulin resistance, can be used for preparing nerve cell protective medicaments and hypoglycemic medicaments, and have practical application values in medical production.
(2) The preparation method of the dihydrocannabidiol dinitrate and the embedding system thereof has the advantages of simple operation, low raw material cost, mild reaction, low energy consumption and high yield.
Detailed Description
Unless defined otherwise, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention relates.
In the present invention, the structural formula and chinese name of the compound used are as follows:
in the invention, the term Pickering emulsion, also called Pickering emulsion, is a novel emulsion which uses solid particles to replace the traditional organic surfactant to stabilize an emulsion system.
In the present invention, the term "room temperature" means that the temperature of an item is close to or the same as the temperature of a space, such as the location of a fume hood in which the item is located. Typically, room temperature is about 20 ℃ to about 30 ℃, or about 22 ℃ to 27 ℃, or about 25 ℃.
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only for illustrating the present invention and should not be construed as limiting the scope of the present invention. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
EXAMPLE 1 preparation of Dihydrocannabidiol derivatives and embedding System therefor
1.1 preparation of the Dihydrocannabidiol derivatives
1.1.1 Synthesis routes to the Dihydrocannabidiol dinitrate
31.4 g (0.1 mol) cannabidiol, 1.57g 10% Pd/C and 200ml anhydrous dichloromethane were added to a 500 mL reactor, nitrogen was replaced 3 times, hydrogen was replaced 3 times, and the reaction was stirred under 2MPa hydrogen for 6 hours. The reaction solution was filtered, concentrated by rotary evaporation, and purified by column chromatography to give a colorless liquid 25.8. 25.8 g in 82% yield.
2.64 g (15 mmol) of 6-chloronicotinyl chloride and 20 mL of anhydrous dichloromethane are added into a 50 mL three-necked flask, stirred, 1.57g (5 mmol) of cannabidiol is added, stirred and reacted for 12 hours at room temperature, concentrated by rotary evaporation, dissolved by dichloromethane, washed by water, dried by anhydrous magnesium sulfate, rotary evaporated, separated and purified by column chromatography to obtain 2.56g of colorless liquid with 86 percent of yield.
The nuclear magnetic hydrogen spectrum of the product is characterized as follows:
1 H NMR (500 MHz, Chloroform-d) δ 9.07 (d,J= 2.4 Hz, 2H), 8.29 (dd,J= 8.3, 2.4 Hz, 2H), 7.42 (d,J= 8.3 Hz, 2H), 6.84 (s, 2H), 5.12 (d,J= 2.7 Hz, 1H), 3.51 – 3.30 (m, 1H), 2.63 – 2.52 (m, 2H), 1.80 – 1.66 (m, 2H), 1.61 – 1.30 (m, 7H), 1.18 (s, 5H), 0.86 – 0.51 (m, 10H). 13 C NMR (126 MHz, Chloroform-d) δ 162.9, 156.4, 151.6, 149.6, 142.8, 140.0, 133.9, 126.8, 124.5, 124.4, 124.3, 43.3, 37.8, 35.2, 31.5, 30.4, 27.9, 26.9, 23.1, 22.4, 22.1, 21.6, 16.3, 14.0.
the high resolution mass spectrum of the product was characterized as follows:
HRMS [M+H] + : theoretical 595.2125 and measured 595.2131.
The nuclear magnetic hydrogen spectrum and the high-resolution mass spectrum detection result show that the preparation method provided by the invention can be used for effectively preparing the dihydrocannabidiol nicotinate.
1.1.2 synthetic routes to the Dihydrocannabidiol dioctanoate
2.43 g (15 mmol) octanoyl chloride and 20 mL anhydrous dichloromethane are added into a 50 mL three-necked flask, stirred, 1.57g (5 mmol) cannabidiol, 1.18g (15 mmol) pyridine and stirred at room temperature are added, the reaction is carried out for 9 hours, the mixture is concentrated by rotary evaporation, the mixture is dissolved by dichloromethane, washed by water, dried by anhydrous magnesium sulfate, rotary evaporated and separated and purified by column chromatography, and colorless liquid is obtained.
The nuclear magnetic hydrogen spectrum of the product is characterized as follows:
1 H NMR (500 MHz, Chloroform-d) δ 6.70 (s, 2H), 5.14 (d,J= 2.4 Hz, 1H), 3.46 – 3.36 (m, 1H), 2.55 (m,J= 9.2, 6.6 Hz, 4H), 2.44 (t,J= 7.5 Hz, 4H), 2.31 (m,J= 29.1, 7.6 Hz, 1H), 1.79 – 1.65 (m, 8H), 1.68 – 1.55 (m, 9H), 1.00 – 0.92 (m, 2H), 0.91 – 0.86 (m, 21H), 0.82 (d,J= 7.0 Hz, 4H), 0.75 (d,J= 6.8 Hz, 3H).
13 C NMR (126 MHz, Chloroform-d)) δ 171.9, 150.0, 141.9, 132.8, 126.4, 125.1, 42.7, 37.5, 35.3, 34.3, 31.7, 30.5, 29.2, 29.0, 27.9, 26.9, 24.7, 24.2, 23.4, 22.6, 22.5, 21.6, 16.1, 14.1.
the high resolution mass spectrum of the product was characterized as follows:
HRMS [M+H] + : theoretical 568.4570 and measured 568.4573.
The nuclear magnetic hydrogen spectrum and the high-resolution mass spectrum detection result show that the preparation method provided by the invention can be used for effectively preparing the dihydrocannabidiol dioctanoate.
1.1.3 synthetic routes to the dihydrocannabidiol diisononanoate
2.64 g (15 mmol) isononyl chloride and 20 mL anhydrous dichloromethane are added into a 50 mL three-necked flask, stirred, 1.57g (5 mmol) cannabidiol and 1.18g (15 mmol) pyridine are added, stirred at room temperature, reacted for 9 hours, concentrated by rotary evaporation, dissolved by dichloromethane, washed by water, dried by anhydrous magnesium sulfate, rotary evaporated, separated and purified by column chromatography, and colorless liquid is obtained.
The nuclear magnetic hydrogen spectrum of the product is characterized as follows:
1 H NMR (500 MHz, Chloroform-d) δ 6.62 (s, 2H), 5.07 (s, 1H), 3.38 – 3.31 (m, 1H), 2.52 – 2.43 (m, 3H), 1.31 – 1.20 (m, 10H), 1.12 (m,J= 14.0, 6.5, 2.4 Hz, 3H), 1.01 (dd,J= 6.6, 2.5 Hz, 8H), 0.90 – 0.84 (m, 26H), 0.83 – 0.80 (m, 4H), 0.75 (d,J= 6.9 Hz, 3H), 0.69 (m,J= 6.9, 2.2 Hz, 3H).
13 C NMR (126 MHz, Chloroform-d)) δ 171.1, 150.0, 141.9, 132.7, 126.3, 125.0, 50.7, 43.8, 42.7, 37.6, 35.2, 31.5, 31.1, 30.9, 30.4, 30.0, 30.0, 27.9, 26.9, 23.4, 22.7, 22.5, 21.5, 14.0.
the high resolution mass spectrum of the product was characterized as follows:
HRMS [M+H] + : theoretical 597.4883 and measured 597.4884.
The nuclear magnetic hydrogen spectrum and the high-resolution mass spectrum detection result show that the preparation method provided by the invention can be used for effectively preparing the dihydrocannabidiol diisononanoate.
1.1.4 synthetic routes to the dihydrocannabidiol dipelargonate
2.65 g (15 mmol) of nonanoyl chloride and 20 mL of anhydrous dichloromethane are added into a 50 mL round bottom flask and stirred, 1.57g (5 mmol) of cannabidiol, 1.18g (15 mmol) of pyridine are added, stirring is carried out at room temperature, reaction is carried out for 12 hours, rotary evaporation concentration is carried out, dichloromethane is used for dissolution, water washing, anhydrous magnesium sulfate drying, rotary evaporation and column chromatography separation and purification are carried out, and colorless liquid is obtained.
The nuclear magnetic hydrogen spectrum of the product is characterized as follows:
1 H NMR (500 MHz, Chloroform-d) δ 6.60 (t,J= 1.0 Hz, 2H), 6.19 (d,J= 9.1, 1.3 Hz, 1H), 3.42 (m,J= 10.1, 9.2, 2.3, 1.0 Hz, 1H), 2.61 – 2.47 (m, 6H), 2.16 – 2.03 (m, 2H), 1.82 – 1.45 (m, 13H), 1.43 – 1.18 (m, 24H), 0.89 (s, 15H).
13 C NMR (125 MHz, Chloroform-d)) δ 171.8, 151.2, 143.2, 138.7, 124.1, 120.2, 115.2, 44.8, 35.8, 35.7, 34.4, 31.3, 31.0, 30.8, 30.7, 29.6, 29.3, 29.2, 24.7, 24.1, 23.4, 22.6, 22.5, 20.0, 14.0 .
the high resolution mass spectrum of the product was characterized as follows:
HRMS [M+H] + : theoretical 597.4883 and measured 597.4889.
The nuclear magnetic hydrogen spectrum and the high-resolution mass spectrum detection result show that the preparation method provided by the invention can be used for effectively preparing the dihydrocannabidiol dipelargonate.
1.1.5 synthetic route to dihydrocannabidiol diacetate
1.53 g (15 mmol) acetic anhydride and 20 mL anhydrous methylene chloride are added into a 50 mL three-necked flask, stirred, 1.57g (5 mmol) cannabidiol, 1.18g (15 mmol) pyridine are added, stirred at room temperature, reacted for 9 hours, concentrated by rotary evaporation, dissolved by methylene chloride, washed by water, dried by anhydrous magnesium sulfate, rotary evaporated, separated and purified by column chromatography, and colorless liquid is obtained.
The nuclear magnetic hydrogen spectrum of the product is characterized as follows:
1 H NMR (500 MHz, Chloroform-d) δ 6.58 (t,J= 1.0 Hz, 2H), 6.19 (d,J= 9.1, 1.3 Hz, 1H), 3.42 (m,J= 10.1, 9.2, 2.8, 0.9 Hz, 1H), 2.57 (tt,J= 7.7, 1.1 Hz, 2H), 2.50 (s, 5H), 2.17 – 2.02 (m, 2H), 1.83 – 1.46 (m, 10H), 1.43 – 1.27 (m, 4H), 0.92 – 0.86 (m, 9H).
13 C NMR (125 MHz, Chloroform-d)) δ 168.1, 151.8, 143.1, 138.7, 124.1, 121.2, 115.6, 44.8, 35.8, 35.7, 31.3, 31.0, 30.8, 29.2, 24.1, 23.4, 22.5, 20.7, 20.0, 14.0.
the high resolution mass spectrum of the product was characterized as follows:
HRMS [M+H] + : theoretical 401.2692 and measured 401.2689.
The nuclear magnetic hydrogen spectrum and the high-resolution mass spectrum detection result show that the preparation method provided by the invention can be used for effectively preparing the dihydrocannabidiol diacetate.
1.1.6 synthetic route to Dihydrocannabidiol Di-p-methylbenzoate
2.31 g (15 mmol) of p-methylbenzoyl chloride and 20 mL of anhydrous dichloromethane are added into a 50 mL three-necked flask, stirred, 1.57g (5 mmol) of cannabidiol and 1.51g of triethylamine (15 mmol) are added, stirred at room temperature for reaction for 6 hours, washed with water, dried over anhydrous magnesium sulfate, distilled, separated and purified by column chromatography, and colorless liquid is obtained.
The nuclear magnetic hydrogen spectrum of the product is characterized as follows:
1 H NMR (500 MHz, Chloroform-dδ 8.21 – 8.16 (m, 4H), 7.52 – 7.49 (m, 4H), 6.89 (d,J= 3.4 Hz, 2H), 5.24 (t,J= 1.9 Hz, 1H), 2.68 – 2.54 (m, 2H), 2.33(s, 6H) 2.03-1.88(m, 2H), 1.73 – 1.49 (m, 10H), 1.39 – 1.26 (m, 4H), 0.95 – 0.76 (m, 9H)
13 C NMR (126 MHz, Chloroform-d) δ 165.0, 150.3, 142.3, 135.3, 133.6, 131.5, 130.1, 128.9, 128.5, 127.1, 124.7, 43.2, 37.7, 35.3, 31.6, 30.5, 27.9, 26.9, 23.0, 22.5, 21.8, 16.3, 14.0.
the high resolution mass spectrum of the product was characterized as follows:
HRMS [M+H] + : theoretical 553.3318 and measured 553.3320.
The nuclear magnetic hydrogen spectrum and the high-resolution mass spectrum detection result show that the preparation method provided by the invention can be used for effectively preparing the dihydrocannabidiol di-p-methyl benzoate.
1.2 preparation of embedding System for Dihydrocannabidiol derivatives
The dihydrocannabidiol dinitrate was dissolved in propylene glycol to prepare an oil solution of dihydrocannabidiol dinitrate having a concentration of 2% (w/v). And (3) carrying out ultrasonic shearing on the oil solution of the dihydrocannabidiol dinitrate and 0.2% (w/v) cellulose nanocrystalline suspension in a ratio of 1:1 to obtain the Pickering emulsion embedded with the dihydrocannabidiol dinitrate. The configuration parameters are as follows: ultrasonic power 400W, ultrasonic time 5min.
The embedding system of other dihydrocannabidiol derivatives (such as dihydrocannabidiol di-p-methyl benzoate, dihydrocannabidiol diisononanoate, dihydrocannabidiol dioctanoate, dihydrocannabidiol diacetate and dihydrocannabidiol dipelargonoate) is prepared by the same method as above.
EXAMPLE 2 determination of neuronal injury protection effect of Dihydrocannabidiol derivatives
Under aseptic conditions, dihydrocannabidiol dinicotinate (prepared in example 1) and analogues thereof (such as cannabidiol-2-imidazole-1-carboxylate, cannabidiol-2-propionate, cannabidiol-2-butyrate, cannabidiol-2-nicotinate, cannabidiol-2- (N-acetyl) piperidine acid ester, cannabidiol-2-pyrrolidone acid ester, cannabidiol-2-piperazine acid ester, cannabidiol-2-dioxopiperazine acid ester) were dissolved in DMSO to prepare a 10 mM mother liquor. Human neuroblastoma cells SH-SY5Y are inoculated into 96-well plates, the compounds are respectively added into culture media, diluted to 5.0, 2.5, 1.0, 0.5, 0.25 and 0.1 mu M, 5 compound holes are set in each group, after 24 hours of culture, a cell damage model is constructed by stimulation of hydrogen peroxide, after 24 hours of continuous culture, 10 mu L of CCK-8 reagent is added into each hole, and the culture is continued for 2 hours. The experiment was carried out in a normal control group and in a SH-SY5Y cell damage group caused by hydrogen peroxide. The cell viability was calculated by measuring OD values in 96-well plates on an enzyme-labeled instrument at a wavelength of 450 nm.
Cell viability (%) = (treatment OD-blank OD)/(control OD-blank OD) ×100%.
The test results are shown in Table 1.
TABLE 1 protection of nerve cell injury by Hydrogen peroxide by different Compounds
Note that: in the SH-SY5Y cell damage caused by hydrogen peroxide as a model, the cell survival rate (%) of a normal control group is 100, and the cell survival rate (%) of the SH-SY5Y cell damage group is 68.67 +/-2.82.
From the results shown in Table 1, it can be seen that the dihydrocannabidiol dinitrate has the effect of antagonizing the oxidative stress of hydrogen peroxide on SH-SY5Y cells, and can improve the cell survival rate. And the activity of the dihydrocannabidiol dinitrate is higher than that of the analogue thereof under the same concentration. The research results show that the dihydrocannabidiol dinitrate has a protective effect on nerve cell injury.
EXAMPLE 3 determination of neuronal injury protection effect of Dihydrocannabidiol derivatives and their embedding System
Under aseptic condition, the dihydrocannabidiol dinicotinate and embedding system thereof (prepared in example 1), other dihydrocannabidiol derivatives and embedding systems thereof (such as dihydrocannabidiol dimethyl benzoate, dihydrocannabidiol diisononanoate, dihydrocannabidiol dicaprylate, dihydrocannabidiol diacetate and dihydrocannabidiol dipelargonate) and CBD are dissolved by DMSO to prepare 10 mM mother solution. Human neuroblastoma cells SH-SY5Y are inoculated into a 96-well plate, the above compounds and Pickering emulsion thereof are respectively added into a culture medium, diluted into 10.0, 2.5, 0.5 and 0.1 mu M of each group of 6 compound wells, after 24 hours of culture, a cell injury model is constructed by stimulation of hydrogen peroxide, after the culture is continued for 24 hours, 10 mu L of CCK-8 reagent is added into each well, and the culture is continued for 2 hours. The experiment was carried out in a normal control group and in a SH-SY5Y cell damage group caused by hydrogen peroxide. The cell viability was calculated by measuring OD values in 96-well plates on an enzyme-labeled instrument at a wavelength of 450 nm.
Cell viability (%) = (treatment OD-blank OD)/(control OD-blank OD) ×100%.
The test results are shown in Table 2.
TABLE 2 protection of different compounds and their embedding systems against SH-SY5Y cell damage by hydrogen peroxide
Note that: in the SH-SY5Y cell damage caused by hydrogen peroxide as a model, the cell survival rate (%) of a normal control group is 100+/-0, and the cell survival rate (%) of the SH-SY5Y cell damage group is 65 67+/-2.82 a 。
As can be seen from the results in Table 2, the CBD and the dihydrocannabidiol derivative and the embedding system thereof have the protection effect on SH-SY5Y cell damage caused by hydrogen peroxide, and the cytoprotection effect of the dihydrocannabidiol derivative and the embedding system thereof is best at 0.5 mu M. After embedding, the cytoprotective activity of the dihydrocannabidiol dinitrate is obviously improved. The activity of the dihydrocannabidiol di-p-methyl benzoate after embedding is obviously improved, and the activity of the dihydrocannabidiol diisopelargonate, the dihydrocannabidiol dioctanoate, the dihydrocannabidiol diacetate and the dihydrocannabidiol dinonoate after embedding also has certain cytoprotective effect, but has no obvious difference with the activity before embedding, and even certain derivatives are reduced relative to the activity before embedding. The research results show that the dihydrocannabidiol derivative and the embedding system thereof have a certain effect of relieving SH-SY5Y cell damage caused by hydrogen peroxide, and the protection effect of the dihydrocannabidiol dinitrate on SH-SY5Y cell damage caused by hydrogen peroxide after embedding is obviously improved.
EXAMPLE 4 determination of insulin resistance of Dihydrocannabidiol derivatives and embedding System thereof
Under aseptic condition, the dihydrocannabidiol dinicotinate and embedding system thereof (prepared in example 1), other dihydrocannabidiol derivatives and embedding systems thereof (such as dihydrocannabidiol dimethyl benzoate, dihydrocannabidiol diisononanoate, dihydrocannabidiol dicaprylate, dihydrocannabidiol diacetate and dihydrocannabidiol dipelargonate) and CBD are dissolved by DMSO to prepare 10 mM mother solution. Human hepatoma cells HepG2 are inoculated into a 96-well plate, an insulin resistance model is built by high-concentration insulin induction, after the culture is carried out for 24 hours, the compounds and Pickering emulsion thereof are added into a culture medium and diluted to 10.0, 2.5, 0.5 and 0.1 mu M respectively, after each group of 6 compound wells is continuously cultured for 24 hours, 5 mu L of supernatant is sucked from each well, 195 mu L of glucose content detection working solution is added, and the culture is incubated for 20 minutes at 37 ℃. Experimental setup of insulin resistance model group, metformin (10 -3 M) positive control group and compound experimental group. The OD value was measured by placing the 96-well plate on an enzyme-labeled instrument at 550 nm wavelength, and the glucose consumption was calculated.
Glucose consumption (μm) =5550- (OD-0.0554 per group)/0.0002.
The test results are shown in Table 3.
TABLE 3 hypoglycemic effects of different Compounds and their embedding systems on insulin-resistant liver cancer cell model
Note that: in the modified insulin resistance model, the glucose consumption of the insulin resistance model group is: 3122.18 + -183.29 a The method comprises the steps of carrying out a first treatment on the surface of the The metformin positive group was: 3845.57 + -103.96 g 。
As can be seen from the results in Table 3, the above-mentioned dihydrocannabidiol derivatives and the embedding system thereof all have the effect of reducing glucose in insulin resistant HepG2 cells, and the compound has the best effect of reducing glucose at 0.5. Mu.M. Among the above compounds, 0.5. Mu.M of the embedded dihydrocannabidiol dinicotinate has the highest hypoglycemic activity, which is closest to that of the positive control group, namely dihydrocannabidiol di-p-methyl benzoate, dihydrocannabidiol diisopelargonate, dihydrocannabidiol dioctanoate, dihydrocannabidiol diacetate and dihydrocannabidiol dinionanoate, has certain hypoglycemic effect after embedding, but has no obvious difference from that before embedding, even certain derivatives have reduced activity compared with that before embedding. The research results show that the dihydrocannabidiol derivative and the embedding system thereof have a certain relieving effect on the insulin resistance of HepG2 cells, and the relieving effect on the insulin resistance of the HepG2 cells is obviously improved after the dihydrocannabidiol dinitrate is embedded.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention.

Claims (10)

1. The preparation method of the embedding system of the dihydrocannabidiol dinitrate is characterized by comprising the following steps of:
(1) Preparation of dihydrocannabidiol dinitrate:
a: mixing cannabidiol, an organic solvent A and a catalytic system to obtain dihydro cannabidiol;
b: mixing the dihydrocannabidiol, the organic solvent B and the 6-chloronicotinyl chloride to obtain dihydrocannabidiol dinicotinate;
(2) Preparing an embedding system:
dissolving the dihydrocannabidiol dinitrate in an organic solvent C to obtain an oil solution, mixing the oil solution with a cellulose nanocrystalline suspension, and shearing to obtain an embedding system of the dihydrocannabidiol dinitrate;
the structure of the dihydrocannabidiol dinitrate is shown in the formula I:
。
2. the preparation method according to claim 1, wherein the organic solvent A is one or more selected from dichloromethane, cyclohexane, methanol, ethanol, isopropanol, diethyl ether, chloroform, propylene glycol, n-butanol, acetone, tetrahydrofuran and xylene;
and/or the catalytic system is a catalyst and/or hydrogen; the catalyst is a metal catalyst and/or a carbon carrier;
and/or the mass ratio of the cannabidiol to the catalytic system is 10-30:1.
3. The method according to claim 2, wherein the metal catalyst is one or more selected from the group consisting of platinum, palladium, rhodium, molybdenum, tin, and uranium;
and/or the carbon carrier is selected from one or more of activated carbon, carbon nano tube, activated carbon fiber, graphene and carbon black;
and/or the pressure of the hydrogen is 1-5 MPa;
and/or the catalytic system is a 10% palladium on carbon catalyst.
4. The preparation method according to claim 1, wherein the organic solvent B is one or more selected from dichloromethane, cyclohexane, methanol, ethanol, isopropanol, diethyl ether, chloroform, propylene glycol, n-butanol, acetone, tetrahydrofuran, and xylene;
and/or the molar ratio of the dihydrocannabidiol to the 6-chloronicotinyl chloride is 1:2-4.
5. The preparation method according to claim 1, wherein the organic solvent C is one or more selected from dichloromethane, cyclohexane, methanol, ethanol, isopropanol, diethyl ether, chloroform, propylene glycol, n-butanol, acetone, tetrahydrofuran, and xylene;
and/or the mass concentration of the oil solution is 0.1-5%;
and/or the volume ratio of the oil solution to the cellulose nanocrystalline suspension is 1:0.1-5;
and/or the shearing method is selected from one or more of ultrasonic shearing, mechanical shearing, laser shearing, thermal shearing and water jet shearing;
and/or, the parameters of ultrasonic shearing are as follows: the ultrasonic power is 100-1000W, and the ultrasonic time is 1-10 min.
6. An embedding system of dihydrocannabidiol dinitrate prepared by the method of any one of claims 1-5.
7. Use of the embedding system of dihydrocannabidiol dinitrate as claimed in claim 6 for the preparation of a hypoglycemic agent.
8. Use of the entrapment system of dihydrocannabidiol dinitrate according to claim 6 for the preparation of a medicament for neuroprotection.
9. The application of the dihydrocannabidiol dinitrate in the preparation of hypoglycemic drugs is characterized in that the structure of the dihydrocannabidiol dinitrate is shown as a formula I:
。
10. a pharmaceutical composition comprising dihydrocannabidiol dinitrate, or a pharmaceutically acceptable salt thereof, or a solvate thereof, or an embedding system of dihydrocannabidiol dinitrate as claimed in claim 6.
CN202311266164.4A 2023-09-28 2023-09-28 Embedding system of dihydrocannabidiol dinitrate and preparation method and application thereof Active CN116983267B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311266164.4A CN116983267B (en) 2023-09-28 2023-09-28 Embedding system of dihydrocannabidiol dinitrate and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202311266164.4A CN116983267B (en) 2023-09-28 2023-09-28 Embedding system of dihydrocannabidiol dinitrate and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN116983267A true CN116983267A (en) 2023-11-03
CN116983267B CN116983267B (en) 2023-12-19

Family

ID=88528776

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202311266164.4A Active CN116983267B (en) 2023-09-28 2023-09-28 Embedding system of dihydrocannabidiol dinitrate and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN116983267B (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099987A1 (en) * 2004-02-16 2007-05-03 Lola Weiss Treating or preventing diabetes with cannabidiol
US20200398184A1 (en) * 2018-08-08 2020-12-24 Neptune Wellness Solutions Inc. Cold extraction method for cannabinoids and terpenes from cannabis by organic solvents
CN113209052A (en) * 2021-03-16 2021-08-06 深圳市泰力生物医药有限公司 Cannabidiol self-nanoemulsion buccal membrane preparation and preparation method and application thereof
CN113966213A (en) * 2019-04-18 2022-01-21 耶路撒冷希伯来大学伊森姆研究发展有限公司 Self-emulsifying drug delivery system for delivery of lipophilic compounds
CN114349695A (en) * 2022-03-07 2022-04-15 中国农业科学院农产品加工研究所 Cannabidiol-2-nicotinate and application thereof
US20220133683A1 (en) * 2020-07-08 2022-05-05 Shaman Naturals, Llc Compositions for preventing and treating diabetes
WO2022223099A1 (en) * 2021-04-19 2022-10-27 Symrise Ag Compositions comprising cannabidiol and, optionally, bisabolol

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099987A1 (en) * 2004-02-16 2007-05-03 Lola Weiss Treating or preventing diabetes with cannabidiol
US20200398184A1 (en) * 2018-08-08 2020-12-24 Neptune Wellness Solutions Inc. Cold extraction method for cannabinoids and terpenes from cannabis by organic solvents
CN113966213A (en) * 2019-04-18 2022-01-21 耶路撒冷希伯来大学伊森姆研究发展有限公司 Self-emulsifying drug delivery system for delivery of lipophilic compounds
US20220133683A1 (en) * 2020-07-08 2022-05-05 Shaman Naturals, Llc Compositions for preventing and treating diabetes
CN113209052A (en) * 2021-03-16 2021-08-06 深圳市泰力生物医药有限公司 Cannabidiol self-nanoemulsion buccal membrane preparation and preparation method and application thereof
WO2022223099A1 (en) * 2021-04-19 2022-10-27 Symrise Ag Compositions comprising cannabidiol and, optionally, bisabolol
CN114349695A (en) * 2022-03-07 2022-04-15 中国农业科学院农产品加工研究所 Cannabidiol-2-nicotinate and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
林謦怡等: "纤维素纳米晶体在Pickering乳液中的应用", 《中国造纸学报》, vol. 1, no. 38, pages 120 - 127 *

Also Published As

Publication number Publication date
CN116983267B (en) 2023-12-19

Similar Documents

Publication Publication Date Title
CN113336705B (en) Cannabidiol-2-imidazole-1-formate and application thereof
CN105884726B (en) The synthetic method and purifying process of butylphenyl phthaleine
EP1809595B1 (en) Process for preparing aloe-emodin
CN113735709B (en) Cannabidiol-2-butyrate and application thereof
Zhou et al. Semi-synthesis and anti-tumor activity of 5, 8-O-dimethyl acylshikonin derivatives
CN113666824B (en) Cannabidiol-2-propionate and application thereof
CN114292249A (en) Cannabidiol-2-piperazinoate and application thereof
CN103396464B (en) A kind of preparation method of ivermectin
CN116983267B (en) Embedding system of dihydrocannabidiol dinitrate and preparation method and application thereof
CN116983263B (en) Embedding system of dihydrocannabidiol diimidazole formate and preparation method and application thereof
CN116983266B (en) Embedding system of dihydrocannabidiol difurancarboxylate and preparation method and application thereof
CN116983264B (en) Embedding system of dihydrocannabidiol dibenzoate as well as preparation method and application thereof
CN116983265B (en) Embedding system of dihydro cannabidiol-2, 6-dioxopiperazine formate and preparation method and application thereof
CN103613568B (en) The preparation method of a kind of Naphtonone and analogue thereof
CN114292241B (en) Cannabidiol-2-dioxopiperazinoate and application thereof
CN107892709B (en) Betulinic ester alcohol derivative, preparation method and application
CN114349695B (en) Cannabidiol-2-nicotinate and application thereof
CN114292224B (en) Cannabidiol-2- (N-acetyl) piperidine acid ester and application thereof
CN114315680B (en) Cannabidiol-2-pyrrolidine acid ester and application thereof
CN113004368B (en) Ursolic acid pyrimidine amide derivatives, and preparation method and application thereof
CN115160399B (en) Soap-skin acid compound, preparation method and medical application thereof
CN113735873B (en) Method for preparing Artemisinin G
CN105884751A (en) Alpha-tocopherol spin labeling derivatives and preparation method thereof
RU2379314C1 (en) Method for making allobetulin
CN113150059A (en) Ursolic acid pyrimidine methyl ester derivative and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240129

Address after: 150431 First Committee of Ben street, Binxi Town, Bin County, Harbin City, Heilongjiang Province

Patentee after: Heilongjiang Fengyou hemp planting Co.,Ltd.

Country or region after: China

Address before: 100193 No. 2 Old Summer Palace West Road, Beijing, Haidian District

Patentee before: INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Country or region before: China